Iterum Therapeutics downgraded by HC Wainwright & Co.
$ITRM
Biotechnology: Pharmaceutical Preparations
Health Care
HC Wainwright & Co. downgraded Iterum Therapeutics from Buy to Neutral
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/27/2021 | Sell → Hold | Gabelli & Co. | |
| 7/26/2021 | Buy → Neutral | HC Wainwright & Co. |
DUBLIN and CHICAGO, July 02, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) ("Iterum" or the "Company"), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced that it has granted a non-statutory share option to purchase an aggregate of 200,000 ordinary shares of Iterum to Christine Coyne, Iterum's newly appointed Chief Commercial Officer. This grant was awarded pursuant to the Nasdaq inducement grant exception as a component of new hire employment compensation. The share option was granted effective July 1, 2025, with an exercise price of $0.97 per share, which is equal to t
DUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) ("Iterum" or the "Company"), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced the appointment of Christine Coyne to the newly created position of Chief Commercial Officer. In this role, Ms. Coyne will lead all commercial efforts for Iterum, including the upcoming launch of ORLYNVAH™ in the United States, as well as future commercialization activities across new products and markets. "We are delighted to welcome Christine to the Iterum leadership team at such a pivotal time for the company," said
DUBLIN and CHICAGO, June 25, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that NEJM Evidence published results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales) Phase 3 clinical trial comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral Augmentin® (amoxicillin/clavulanate) in adult women with uncomplicated urinary tract infections (uUTIs) https://evidence.nejm.org/
Gabelli & Co. upgraded Iterum Therapeutics from Sell to Hold
HC Wainwright & Co. downgraded Iterum Therapeutics from Buy to Neutral
Gabelli & Co upgraded Iterum Therapeutics from Sell to Hold
4 - Iterum Therapeutics plc (0001659323) (Issuer)
3 - Iterum Therapeutics plc (0001659323) (Issuer)
3 - Iterum Therapeutics plc (0001659323) (Issuer)
DUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) ("Iterum" or the "Company"), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced the appointment of Christine Coyne to the newly created position of Chief Commercial Officer. In this role, Ms. Coyne will lead all commercial efforts for Iterum, including the upcoming launch of ORLYNVAH™ in the United States, as well as future commercialization activities across new products and markets. "We are delighted to welcome Christine to the Iterum leadership team at such a pivotal time for the company," said
DUBLIN, Ireland and CHICAGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the appointment of Sailaja Puttagunta, M.D., to the newly created position of Chief Medical Officer, where she will oversee global clinical development and regulatory initiatives for Iterum. "We are thrilled that Sailaja is back at Iterum given her strong industry and operational leadership at a time when oral sulopenem is re-entering the clin
Patrick Heron to leave the Board DUBLIN, Ireland and CHICAGO, March 16, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the appointment of Beth P. Hecht to the Company’s Board of Directors replacing Patrick Heron, who announced he would be leaving the Board, effective as of March 12, 2021. Ms. Hecht will also serve as a member of the Audit Committee and Compensation Committee of the Board. “I want to thank Patrick for his leade
U.S. Commercial Launch of ORLYNVAHTM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at 4:30 p.m. ET today DUBLIN and CHICAGO, June 11, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that it entered into a Product Commercialization Agreement (the "Agreement") with EVERSANA Life Science Services, LLC ("EVERSANA") for the commercialization of the Company's approved product, ORLYNVAHTM. Pursuant to the Agreement, EVERSA
DUBLIN, Ireland and CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business. To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Access
--ORLYNVAHTM Approved by FDA in Q4 2024— --Extended Cash Runway-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter and year ended December 31, 2024. "While outreach to potential strategic partners is our priority and ongoing, we have begun pre-commercialization work to ensure ORLYNVAHTM is made available to patients as soon as possible to address the substantial u
8-K - Iterum Therapeutics plc (0001659323) (Filer)
8-K - Iterum Therapeutics plc (0001659323) (Filer)
10-Q - Iterum Therapeutics plc (0001659323) (Filer)
4 - Iterum Therapeutics plc (0001659323) (Issuer)
4 - Iterum Therapeutics plc (0001659323) (Issuer)
4 - Iterum Therapeutics plc (0001659323) (Issuer)
SC 13G/A - Iterum Therapeutics plc (0001659323) (Subject)
SC 13G - Iterum Therapeutics plc (0001659323) (Subject)
SC 13G - Iterum Therapeutics plc (0001659323) (Subject)